| 84.59 Delayed Data As of Jan 18 |  +0.34 / +0.40%Today’s Change | 70.20 Today|||52-Week Range 96.57 | -1.11% Year-to-Date |
| Why the Earnings Surprise Streak Could Continue for Zoetis (ZTS) Jan 18 / Zacks.com - Paid Partner Content |
| Previous close | 84.25 |
| Today’s open | 84.62 |
| Day’s range | 83.58 - 85.15 |
| Volume | 3,059,017 |
| Average volume (3 months) | 2,358,447 |
| Market cap | $42.6B |
| Earnings growth (last year) | +6.02% |
| Earnings growth (this year) | +29.64% |
| Earnings growth (next 5 years) | +14.20% |
| Revenue growth (last year) | +8.57% |
| P/E ratio | 35.5 |
| Price/Sales | 6.69 |
| Price/Book | 24.36 |
| Today’s change | Today’s % change | |
|---|---|---|
| VRTXVertex Pharmaceutica... | +4.18 | +2.19% |
| CELGCelgene | -0.32 | -0.37% |
| REGNRegeneron Pharmaceut... | +1.46 | +0.35% |
| AGNAllergan | +3.66 | +2.34% |
| Next reporting date | February 14, 2019 |
| EPS forecast (this quarter) | $0.77 |
| Annual revenue (last year) | $5.3B |
| Annual profit (last year) | $864.0M |
| Net profit margin | 16.28% |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
Chief Executive Officer & Director Juan Ramón Alaix |
Executive Vice President & President-US Operations Kristin C. Peck |
Corporate headquarters New Jersey, New Jersey |
